We are so proud that CURE has chosen HopeWatch as a fundraising option. CURE is a great organization and we really believe in their vision. They are also incredibly nice, extremely committed, and truly inspiring.
Here's a brief bit about CURE:
Their mission is simple, CURE Childhood Cancer is dedicated to discovering cures for childhood cancer through cutting edge research and providing education and support to patients and their families.
Their vision is inspiring: CURE Childhood Cancer believes that childhood cancers can be cured in our lifetime.
We're dedicated to helping them do this one watch at a time.
Since its inception in 1975, CURE has focused its efforts on improving the care, quality of life, and survival rate of children with cancer. The founders, parents, and a dedicated pediatric oncologist, joined forces to support laboratory research that would translate into immediate care for children with cancer.
CURE was founded in 1975 by Dr. Abdel Ragab, head of the newly established Division of Pediatric Hematology/Oncology at Emory University. Dr. Ragab was the first pediatric oncologist at Emory. Because of the urgent need to fund a pediatric oncology research program at Emory and to provide support for families afflicted by childhood cancer, Dr. Ragab organized a group of parents who formed CURE Childhood Cancer.
CURE’s first mission was to help raise funds for a special microscope and other equipment to assist in diagnosing different types of childhood leukemia, using newly developed techniques. In 1978, CURE contributed $20,000 dollars to purchase the microscope and related research equipment. Additionally, CURE was soon able to provide partial support for the training of Pediatric Hematology/Oncology fellows during their research rotations.
From 1975 to 1981, the childhood cancer research lab was located at Grady Hospital. Since most of Dr. Ragab’s patients were being treated at Emory Clinic, CURE provided a significant donation in 1981 to establish a research lab on the Emory campus. This was designed as a temporary facility while plans were made to build a permanent lab on the campus. Finally, in 1987, a new outpatient clinic for childhood cancer was opened on the campus. Over several years, CURE raised more than one-million dollars to build and equip a laboratory on the second floor of the pediatric oncology clinic. The Childhood Cancer Research lab was dedicated in 1989. The lab represented a huge step forward in providing an up-to-date facility with almost 3,500 sq. feet of space devoted to research in childhood cancer, the first of its kind at Emory.
Under Dr. Ragab’s leadership and with CURE’s backing, the childhood cancer research program at Emory continued to grow and soon became one of the largest pediatric oncology programs in the country in terms of patients diagnosed and treated each year. Besides supporting research, CURE soon made another great contribution to the treatment of childhood cancer by promoting passage of an act in the Georgia legislature titled Calloway’s Law. The act was named in memory of Calloway Thrash, an early patient of Dr Ragab and the son of one of the first presidents of CURE. While being treated for leukemia, Calloway had been unable to obtain insurance coverage for an experimental drug. After Calloway’s death from leukemia, his father and CURE successfully lobbied the Georgia legislature in support of a bill that would mandate Georgia insurers to support experimental therapies for childhood cancer. The passage of this act in the late 1990s was a great advance in support of pediatric cancer clinical trials.
As an outgrowth of basic and clinical research funded by CURE, a number of new therapies were tested at Emory beginning in the 1980s, including the first trial of retinoic acid in pediatric acute myeloid leukemia and the first trial of interleukin-2 for stimulating the immune system in childhood cancer patients. These trials were supported by research performed in the Childhood Cancer Research Laboratory at Emory. Later, in collaboration with the National Cancer Institute, this research included the first laboratory testing of a new drug (BL22) targeted at pediatric acute lymphoblastic leukemia (ALL), a major type of childhood cancer. Using data from this research, the NCI obtained approval for a clinical trial testing BL22 in ALL. Results from this trial have been promising and have led to a trial for a second-generation form of BL22 (called HA22), which is now ongoing with even more promising results. Funding from CURE was critical in supporting the Emory-NCI research collaboration which led to these trials.
Since that time, CURE has raised millions of dollars to fund cutting edge research at the Aflac Cancer Center and Blood Disorders Service at Children's Healthcare of Atlanta and Emory University School of Medicine. Through innovative programming, CURE also provides crisis-oriented support for stricken families aimed at addressing their most critical and urgent needs.
Now our president and founder, Dyan Smoltz, has had experience with childhood cancer. Her nephew was diagnosed with cancer at a very young age. Fortunately, he is now a cancer survivor and cancer free.
We came in contact with CURE due to Golsen Family Dentistry. They generously accepted to sell HopeWatch and selected CURE as their charity. Subsequently, Debbie Driskell saw HopeWatch at Golsen and decided to carry them at All Around Gymnastics. From their I contacted CURE and since then we have been working together to spread the word about CURE and raise money for this incredible organization. They have been dedicated to their mission for 35 years. So here's a secret for the CURE supporters, enter the promo code: BUY5GETONEFREE and you'll do just that. We'll send you 1 free watch when you buy 5.
Make sure you select CURE as your charity when you are checking out so they can receive the donation.
A very special thanks to Angela Murphy for getting us in touch with CURE, and to Kristin and Ashley from CURE. Please visit their site for more information and help spread the word about their work. www.CUREChildhoodCancer.org.